Chronic obstructive pulmonary disease (COPD), lung cancer, interstitial lung disease, pneumonia
Conditions
Interventions
Fondaparinux sodium:5 mg, QD, subcutaneous injection, 7-14 days.
Low molecular weight heparin:4000 axaiu (0.4 ml), QD, subcutaneous injection, 7-14 days
Sponsors
Tianjin Medical University General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Hospitalized patients with respiratory diseases over 18 years old; 2. Patients who need anticoagulant drugs to prevent VTE according to Padua score >= 4; 3. Patients or legal representatives have been informed of the nature of the study and understand the provisions in the protocol to ensure compliance.
Exclusion criteria
Exclusion criteria: 1. Allergy or contraindication to fondaparinux and enoxaparin; 2. High risk of bleeding: patients or history of hemorrhagic diseases, bleeding tendency, bleeding constitution or coagulation disorders; 3. Patients with hyperthyroidism and severe hepatic and renal insufficiency were contraindicated; 4. Having participated in the research of other drugs / devices or during the follow-up period of another drug / device research; 5. Patients may not comply with the research protocol (including the follow-up period), such as mental disorders, alcohol or drug abuse, etc..
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 7-day thrombotic events (including lower extremity deep vein thrombosis, pulmonary embolism, and intraductal thrombosis);7-day bleeding event (any bleeding event, thrombocytopenia); | — |
Secondary
| Measure | Time frame |
|---|---|
| 30 day bleeding events; | — |
Countries
China
Contacts
Public ContactJie Cao
General Hospital of Tianjin Medical University
Outcome results
None listed